Proposed rule 2026-14073
Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The Food and Drug Administration (FDA, the Agency, or we) is proposing to amend the drug establishment registration and drug listing requirements with respect to establishments engaged in distributed manufacturing and foreign drug establishments. This action, if finalized, will provide a pathway for a distributed manufacturing establishment that manufactures drugs at multiple different physical locations to register as a single drug manufacturing establishment and align drug establishment registration and drug listing regulations applicable to foreign drug establishments with statutory changes made by the Preparing for and Responding to Existing Viruses, Emerging New Threats, and Pandemics Act (PREVENT Pandemics Act).
Source-supplied record
Document details
- Document number
- 2026-14073
- Published
- Jul 13, 2026
- Effective
- Not supplied
- Comments close
- Sep 11, 2026 (open)
- Federal Register citation
- 91 FR 42888
Docket identifiers
- Docket No. FDA-2025-N-6075
CFR references
- Title 21, part 207